These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16957942)

  • 1. Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells.
    Kersting G; Tzvetkov MV; Huse K; Kulle B; Hafner V; Brockmöller J; Wojnowski L
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Oct; 374(1):21-30. PubMed ID: 16957942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues.
    Trevino AV; Woynarowska BA; Herman TS; Priebe W; Woynarowski JM
    Mol Cancer Ther; 2004 Nov; 3(11):1403-10. PubMed ID: 15542779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
    Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.
    Chikamori K; Hill JE; Grabowski DR; Zarkhin E; Grozav AG; Vaziri SA; Wang J; Gudkov AV; Rybicki LR; Bukowski RM; Yen A; Tanimoto M; Ganapathi MK; Ganapathi R
    Leukemia; 2006 Oct; 20(10):1809-18. PubMed ID: 16932348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
    Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
    Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226.
    Wang H; Jiang Zg; Wong YW; Dalton WS; Futscher BW; Chan VT
    Biochem Biophys Res Commun; 1997 Aug; 237(2):217-24. PubMed ID: 9268689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
    Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
    Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
    McPherson JP; Brown GA; Goldenberg GJ
    Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of multidrug resistance‑related proteins in adriamycin‑resistant (pumc‑91/ADM) and parental (pumc‑91) human bladder cancer cell lines.
    Zhao M; Yu S; Zhang M
    Mol Med Rep; 2016 Nov; 14(5):4741-4746. PubMed ID: 27748815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
    Willmore E; Errington F; Tilby MJ; Austin CA
    Biochem Pharmacol; 2002 May; 63(10):1807-15. PubMed ID: 12034365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
    Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
    Leukemia; 1996 Jul; 10(7):1177-80. PubMed ID: 8683999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells.
    Gruber BM; Anuszewska EL; Bubko I; Goździk A; Fokt I; Priebe W
    Arch Immunol Ther Exp (Warsz); 2007; 55(3):193-8. PubMed ID: 17557149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
    Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
    Leukemia; 1996 Jul; 10 Suppl 3():S46-S49. PubMed ID: 8656700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy.
    Martin-Richard M; Muñoz M; Albanell J; Colomo L; Bellet M; Rey MJ; Tabernero J; Alonso C; Cardesa A; Gascon P; Fernandez PL
    Oncology; 2004; 66(5):388-94. PubMed ID: 15331926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.